Home
Exegenesis Bio

Exegenesis Bio Market Share Analysis for June 2026

Industry: N/A

Domainexegenesisbio.com

Year Founded2019

Employees51 - 200

Annual Revenue--

Exegenesis Bio

Exegenesis Bio (including company regionals)

exegenesisbio.com

See more website traffic and engagement information

Total visits to Exegenesis Bio's top domains

Understand Exegenesis Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

exegenesisbio.com2.1K

See more with Sales Intelligence

Avg. visit duration in Exegenesis Bio's top domains

Analyze Exegenesis Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

exegenesisbio.com00:00:34

See more with Sales Intelligence

Avg. pageviews on Exegenesis Bio's top domains

See how Exegenesis Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

exegenesisbio.com2.66

See more with Sales Intelligence

Exegenesis Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Exegenesis Bio

These are the website technologies, by industry, used by Exegenesis Bio top domains

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Other (1)

Google API

More Technologies

1

See all

News & Signals from Exegenesis Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsExegenesis Bio attended event ASGCT 29th Annual Meeting on May 11th '26.Exegenesis Bio to present data on delivery platform, bbb-penetrating AAV capsid and research programs at ASGCT 29th Annual Meeting.

NewsExegenesis Bio attended event 28th Annual Meeting of the American Society of Gene and Cell Therapy on May 13th '25.PHILADELPHIA, PA, May 13, 2025 - Exegenesis Bio, a global gene therapy company developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce that two oral presentations and three posters will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 13-17, 2025 in New Orleans, LA.

NewsExegenesis Bio is developing EXG202.Exegenesis Bio is developing a next generation version, EXG202, that incorporates the same genetic cargo, but is delivered to deep retinal cells by a highly-specific ocular capsid that enables administration by intravitreal injection, a less invasive, non-surgical approach.